Formation | September 2009 |
---|---|
Founded at | Connecticut, United States |
Type | Non-profit organization |
Purpose | To raise research funds for Dravet's syndrome and related epilepsies |
Website | www |
The Dravet Syndrome Foundation (DSF) is a volunteer-run, non-profit organization based in the United States. The mission of the foundation is to raise research funds for Dravet's syndrome and related epilepsies, while providing support to affected individuals and families. The Dravet Syndrome Foundation is listed as a research and support organization on National Organization of Rare Diseases's (NORD) database. [1]
The Dravet Syndrome Foundation was founded by parents with the purpose of expediting research to find a cure and better treatments for their afflicted children. [2] It was established in the state of Connecticut and was designated a tax-exempt public charity in the United States in September 2009 by the Internal Revenue Service under Section 501(c)3.
The Dravet Syndrome Foundation focuses its work in four areas: research grants; Research Roundtable; International Ion Channel Epilepsy Patient Registry (IICEPR); and the International Patient Assistance Grant (PAG) Program.
Grants are offered for research projects and postdoctoral fellowships directly related to Dravet syndrome and associated epilepsies. These grants fund initial research hypotheses that have not been fully explored. The results extracted from this type of research will help bring untested research to the point that it can qualify for larger governmental funding. Research applications are judged principally on novelty of the hypotheses, innovative approaches with a direct relevance and application to Dravet syndrome and related conditions, scientific quality, strength of approach, and likelihood of success.
This annual meeting allows researchers, geneticists, neurologists, and other professionals with a strong interest in Dravet syndrome and related epilepsies to establish a "research roadmap". By allowing this consortium of specialists to establish a plan, the Dravet Syndrome Foundation can facilitate the development and implementation of better treatments by funding research projects that address the critical challenges of this syndrome and which will offer the most promising breakthroughs at the fastest pace possible. This meeting takes place each year just prior to the commencement of the American Epilepsy Society (AES) Conference.
This three-day event is designed to unite all groups committed to improving the lives of those with Dravet syndrome – including families, caregivers, clinicians, researchers and professionals in the pharmaceutical industry. There are speaker presentations on the latest advances in research as well as sessions with up to date information impacting patient care. This event allows the opportunity to foster new relationships and collaborations, both for families and professionals. It is held on even-numbered years at locations across the U.S.
This registry (co-funded with ICE Epilepsy Alliance) is owned by University of Michigan Neurology Department and Miami Children's Hospital Brain Institute but is available to all interested researchers. It will collect basic information and genetic test results of individuals with Dravet syndrome and related epilepsies worldwide. The establishment of this registry will expedite future clinical trials and will serve to improve communication of ideas amongst interested researchers, as well as assure rapid distribution of any new information that may benefit patients and their families.
This program offers grants to patients with Dravet syndrome and associated epilepsies for necessary medical equipment needs associated with these conditions that are not covered through private insurance or other assistance programs. [3]
The Dravet Syndrome Foundation’s scientific advisory board (SAB) oversees the organization’s research activities. They review and approve all research grant applications and meet annually with other interested researchers and scientists to discuss innovative and promising research in the field of Dravet syndrome and associated epilepsies at DSF’s Research Roundtable.
In addition to private donations, private fundraising events, corporate sponsorships and grants, the Dravet Syndrome Foundation produces annual fundraising events.
City Bash is the Dravet Syndrome Foundation's annual signature event where money is raised for research while honoring a professional who has gone above and beyond in the field of Dravet syndrome and related epilepsies. Steps Toward A Cure consists of family-friendly fundraising walks across the U.S, organized by families. Race for Research allows athletes to participate in an event of their choosing, while raising funds for DSF.
In 2011, a group of parents formed a delegation of the Dravet Syndrome Foundation in Spain (DSF Spain). Both organizations work closely together, but have separate boards of directors and scientific advisory boards. DSF Spain announced its first research grant award in summer 2011.
The Dravet Syndrome Foundation works with the following like-minded organizations to assure rapid distribution of information and to avoid duplication of efforts and research dollars.
The Dravet Syndrome Foundation (DSF) was established in 2009 to increase research for Dravet syndrome. Their strategy has been to invest in researchers with $50,000–150,000 grants for 1–2 year projects, with the hope that they will use those preliminary studies to apply for larger NIH grants, establishing their place in the field of epilepsy research and DS in particular.
Since its inception in 2009, DSF has awarded over $3.6M in research grants and postdoctoral fellowships.
In the eight years prior to DSF’s founding, from 2002–2009, NIH spent only $6.3 million on projects mentioning Dravet syndrome (DS) or Severe Myoclonic Epilepsy of Infancy (SMEI). Only about 30 studies were published on DS. In the eight years since DSF’s founding, from 2010–2017, NIH spent $44.6 million on projects mentioning DS or SMEI, or seven times the research dollars. Over 300 studies were published on DS. There was an explosion of federal dollars spent on DS between 2010 and 2014, when DSF was first raising awareness and funding in the research world while investing in researchers. Of the 19 researchers DSF invested in through 2015, six of them went on to receive large NIH grants, for a return rate of 32%.
Research awards can be broken down in the following categories for total funding of $3,698,000:
Absence seizures are one of several kinds of generalized seizures. In the past, absence epilepsy was referred to as "pyknolepsy," a term derived from the Greek word "pyknos," signifying "extremely frequent" or "grouped".These seizures are sometimes referred to as petit mal seizures ; however, usage of this terminology is no longer recommended. Absence seizures are characterized by a brief loss and return of consciousness, generally not followed by a period of lethargy. Absence seizures are most common in children. They affect both sides of the brain.
Myoclonus is a brief, involuntary, irregular twitching of a muscle, a joint, or a group of muscles, different from clonus, which is rhythmic or regular. Myoclonus describes a medical sign and, generally, is not a diagnosis of a disease. These myoclonic twitches, jerks, or seizures are usually caused by sudden muscle contractions or brief lapses of contraction. The most common circumstance under which they occur is while falling asleep. Myoclonic jerks occur in healthy people and are experienced occasionally by everyone. However, when they appear with more persistence and become more widespread they can be a sign of various neurological disorders. Hiccups are a kind of myoclonic jerk specifically affecting the diaphragm. When a spasm is caused by another person it is known as a provoked spasm. Shuddering attacks in babies fall in this category.
The Leukemia & Lymphoma Society (LLS), a 501(c)(3) charitable organization founded in 1949, is the largest voluntary health organization dedicated to fighting blood cancer in the world. The LLS's mission is to cure leukemia, lymphoma, Hodgkin's lymphoma and myeloma, and improve the quality of life of patients and their families.
The Northwestern University Dance Marathon, commonly known as NUDM, is a philanthropic dance marathon held every March at Northwestern University in Evanston, Illinois. Founded in 1975, NUDM is one of the nation's most established and largest entirely student-run philanthropies. NUDM is one of the only annual Dance Marathons in the country to continually change its primary beneficiary. NUDM has raised over $1 million for its beneficiaries each year since 2011, and involves over 1,000 students participating as dancers and committee members. Since 1997, the Evanston Community Foundation has been NUDM's secondary beneficiary.
The Children's Tumor Foundation (CTF) is a 501(c)(3) foundation dedicated to improving the health and well-being of individuals and families affected by NF, a group of genetic conditions known as neurofibromatosis or schwannomatosis. Their four-part mission includes propelling drug research and development through a series of strategic investments, strengthening patient support, increasing public awareness of NF and establishing best practices in clinical care for affected individuals. The Foundation is incorporated in all 50 states with active chapters and affiliates in 37 states. CTF is the largest private funder of all forms of NF research.
MERRF syndrome is a mitochondrial disease. It is extremely rare, and has varying degrees of expressivity owing to heteroplasmy. MERRF syndrome affects different parts of the body, particularly the muscles and nervous system. The signs and symptoms of this disorder appear at an early age, generally childhood or adolescence. The causes of MERRF syndrome are difficult to determine, but because it is a mitochondrial disorder, it can be caused by the mutation of nuclear DNA or mitochondrial DNA. The classification of this disease varies from patient to patient, since many individuals do not fall into one specific disease category. The primary features displayed on a person with MERRF include myoclonus, seizures, cerebellar ataxia, myopathy, and ragged red fibers (RRF) on muscle biopsy, leading to the disease's name. Secondary features include dementia, optic atrophy, bilateral deafness, peripheral neuropathy, spasticity, or multiple lipomata. Mitochondrial disorders, including MERRFS, may present at any age.
The National Psoriasis Foundation (NPF) is one of the world's largest nonprofit organization serving people with psoriasis and psoriatic arthritis. The NPF provides information and services to help people manage their condition while supporting research to find a cure. In addition to serving more than 3 million people annually through patient and professional health education and advocacy initiatives, the NPF has funded more than $10 million in psoriatic disease research grants and fellowships.
Generalized epilepsy with febrile seizures plus (GEFS+) is a syndromic autosomal dominant disorder where affected individuals can exhibit numerous epilepsy phenotypes. GEFS+ can persist beyond early childhood. GEFS+ is also now believed to encompass three other epilepsy disorders: severe myoclonic epilepsy of infancy (SMEI), which is also known as Dravet's syndrome, borderline SMEI (SMEB), and intractable epilepsy of childhood (IEC). There are at least six types of GEFS+, delineated by their causative gene. Known causative gene mutations are in the sodium channel α subunit genes SCN1A, an associated β subunit SCN1B, and in a GABAA receptor γ subunit gene, in GABRG2 and there is another gene related with calcium channel the PCDH19 which is also known as Epilepsy Female with Mental Retardation. Penetrance for this disorder is estimated at 60%.
Dravet syndrome, previously known as severe myoclonic epilepsy of infancy (SMEI), is an autosomal dominant genetic disorder which causes a catastrophic form of epilepsy, with prolonged seizures that are often triggered by hot temperatures or fever. It is very difficult to treat with anticonvulsant medications. It often begins before one year of age, with six months being the age that seizures, characterized by prolonged convulsions and triggered by fever, usually begin.
Progressive Myoclonic Epilepsies (PME) are a rare group of inherited neurodegenerative diseases characterized by myoclonus, resistance to treatment, and neurological deterioration. The cause of PME depends largely on the type of PME. Most PMEs are caused by autosomal dominant or recessive and mitochondrial mutations. The location of the mutation also affects the inheritance and treatment of PME. Diagnosing PME is difficult due to their genetic heterogeneity and the lack of a genetic mutation identified in some patients. The prognosis depends largely on the worsening symptoms and failure to respond to treatment. There is no current cure for PME and treatment focuses on managing myoclonus and seizures through antiepileptic medication (AED).
Sodium channel protein type 1 subunit alpha (SCN1A), is a protein which in humans is encoded by the SCN1A gene.
The mission of the Foundation Fighting Blindness is to fund research that will lead to the prevention, treatment and cures for the entire spectrum of retinal degenerative diseases, including retinitis pigmentosa, macular degeneration, Usher syndrome, Stargardt disease and related conditions. These diseases, which affect more than 10 million Americans and millions more throughout the world, often lead to severe vision loss or complete blindness.
Mitochondrially encoded tRNA lysine also known as MT-TK is a transfer RNA which in humans is encoded by the mitochondrial MT-TK gene.
The International Fibrodysplasia Ossificans Progressiva Association (IFOPA) is a US-based 501(c)(3) non-profit organization supporting medical research, education and communication for those afflicted by the rare genetic condition Fibrodysplasia Ossificans Progressiva (FOP). IFOPA's mission is to fund research to find a cure for FOP while supporting, connecting, and advocating for individuals with FOP and their families, and raising awareness worldwide. IFOPA is governed by a volunteer board of directors which may range in number from 9 to 15, at least one of whom must have FOP. The association's location is 1520 Clay St., Suite H2, North Kansas City, MO, 64116, part of the Kansas City, Missouri metropolitan area.
The International Dravet Epilepsy Action League is an American non-profit organization that has created an international partnership of parents and professionals with the purpose of creating greater awareness and understanding of Dravet syndrome and the spectrum of related genetic forms of epilepsy. The IDEA League is a nonprofit organization that was founded by parents of children with Dravet syndrome in October 2005. The National Institutes of Health direct individuals seeking information on Dravet Syndrome to the IDEA League. The IDEA League represents Dravet Syndrome and is a member of the National Organization for Rare Disorders (NORD).
Epilepsy-intellectual disability in females also known as PCDH19 gene-related epilepsy or epileptic encephalopathy, early infantile, 9 (EIEE9), is a rare type of epilepsy that affects predominately females and is characterized by clusters of brief seizures, which start in infancy or early childhood, and is occasionally accompanied by varying degrees of cognitive impairment. The striking pattern of onset seizures at a young age, genetic testing and laboratory results, potential developmental delays or developmental regression and associated disorders, eases diagnosis.
Spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME), sometimes called Jankovic–Rivera syndrome, is a very rare neurodegenerative disease whose symptoms include slowly progressive muscle (atrophy), predominantly affecting proximal muscles, combined with denervation and myoclonic seizures. Only 12 known human families are described in scientific literature to have SMA-PME.
People with epilepsy may be classified into different syndromes based on specific clinical features. These features include the age at which seizures begin, the seizure types, and EEG findings, among others. Identifying an epilepsy syndrome is useful as it helps determine the underlying causes as well as deciding what anti-seizure medication should be tried. Epilepsy syndromes are more commonly diagnosed in infants and children. Some examples of epilepsy syndromes include benign rolandic epilepsy, childhood absence epilepsy and juvenile myoclonic epilepsy. Severe syndromes with diffuse brain dysfunction caused, at least partly, by some aspect of epilepsy, are also referred to as epileptic encephalopathies. These are associated with frequent seizures that are resistant to treatment and severe cognitive dysfunction, for instance Lennox-Gastaut syndrome and West syndrome.
Charlotte Dravet is a French paediatric psychiatrist and epileptologist.
SYNGAP1-related intellectual disability is a monogenetic developmental and epileptic encephalopathy that affects the central nervous system. Symptoms include intellectual disability, epilepsy, autism, sensory processing deficits, hypotonia and unstable gait.